The use of animal testing has significant benefits in medical research; however, increased costs, extremely high failure rates, and delays in drug approval have led many to re-evaluate its value in drug development.
Between 2012 and 2016, China’s biopharma market grew from $9.4 billion to $22.8 billion, and the market is expected to touch $48.8 billion in sales by 2022.1